Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer D Stone

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Biological Chemistry|September 4, 2003
Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1Zarixia Zavala-Ruiz, Eric J Sundberg, Jennifer D Stone, et al.
Nature Chemical Biology|March 1, 2006
Noble metals strip peptides from class II MHC proteinsStephen L De Wall, Corrie Painter, Jennifer D Stone, et al.
Biochemistry|November 1, 2008
Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptorsLindsay L Jones, Leremy A Colf, Alexander J Bankovich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2017
Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition DomainsDaniel T Harris, Marlies V Hager, Sheena N Smith, et al.
Molecular Immunology|October 12, 2005
Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitopePhilip J Norris, Jennifer D Stone, Nadezhda Anikeeva, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2019
Breaking tolerance with engineered class I antigen-presenting moleculesChristopher A Parks, Kalli R Henning, Kevin D Pavelko, et al.
Cancer Research|October 28, 2025
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing TumorsJennifer D Stone, Kamonwan Fish, Devika Ashok, et al.
Molecular Cancer Therapeutics|June 9, 2023
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic MalignanciesAdam S Chervin, Jennifer D Stone, Iwona Konieczna, et al.
Immunity|June 23, 2016
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control AdenocarcinomaAvery D Posey, Robert D Schwab, Alina C Boesteanu, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Biological Chemistry|September 4, 2003
Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1Zarixia Zavala-Ruiz, Eric J Sundberg, Jennifer D Stone, et al.
Nature Chemical Biology|March 1, 2006
Noble metals strip peptides from class II MHC proteinsStephen L De Wall, Corrie Painter, Jennifer D Stone, et al.
Biochemistry|November 1, 2008
Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptorsLindsay L Jones, Leremy A Colf, Alexander J Bankovich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2017
Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition DomainsDaniel T Harris, Marlies V Hager, Sheena N Smith, et al.
Molecular Immunology|October 12, 2005
Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitopePhilip J Norris, Jennifer D Stone, Nadezhda Anikeeva, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 8, 2019
Breaking tolerance with engineered class I antigen-presenting moleculesChristopher A Parks, Kalli R Henning, Kevin D Pavelko, et al.
Cancer Research|October 28, 2025
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing TumorsJennifer D Stone, Kamonwan Fish, Devika Ashok, et al.
Molecular Cancer Therapeutics|June 9, 2023
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic MalignanciesAdam S Chervin, Jennifer D Stone, Iwona Konieczna, et al.
Immunity|June 23, 2016
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control AdenocarcinomaAvery D Posey, Robert D Schwab, Alina C Boesteanu, et al.
Pageof 3